$ESLA News

Estrella Immunopharma Q1 EPS $(0.05) Beats $(0.18) Estimate

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target

Estrella Immunopharma Presents Updated EB103 Data Showing 100% Complete Response In High-Dose Cohort At 2026 ASTCT And CIBMTR Tandem Meetings

Estrella Immunopharma Presents Updated EB103 Data Showing 100% Complete Response In High-Dose Cohort At 2026 ASTCT And CIBMTR Tandem Meetings

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma To Present Late-Breaking Phase 1 Data For EB103 in Aggressive B-Cell NHL At 2026 ASTCT & CIBMTR Tandem Meetings

Estrella Immunopharma To Present Phase 1 STARLIGHT-1 Data For EB103 At 2026 Tandem Meetings Of ASTCT & CIBMTR

D. Boral Capital Maintains Buy on Estrella Immunopharma, Lowers Price Target to $8

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma Announces Registered Direct Offering And Concurrent Private Placement; Aggregate Gross Proceeds From Both Transactions Expected To Be ~$8M

Estrella Immunopharma Offers Up To 2,541,206 Shares For Resale By The Selling Stockholders

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Recommended By Independent Data Safety Monitoring Board To Advance STARLIGHT-1 Study To Phase II After Review Of Safety Data

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

Estrella Immunopharma Completes Second Dose Cohort In STARLIGHT-1 Phase I/II Clinical Trial Of EB103